The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

"When I was about 28, I was like; 'I've had enough'. I demanded that I see a gynaecologist or I would go to the complaints ...

After being prompted by a friend who saw the dreadful way she was being treated, Carla went to different specialists for a ...

Everest Medicines, today announced the presentation of maintenance data from its multi-center Phase III clinical study of ...

Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) ...

Jefferies lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $42 from $53 and keeps a Buy rating on the shares. For the FY24 ...

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

Eli Lilly is buying Organovo’s farnesoid X receptor (FXR) agonist program, which includes a drug in Phase 2 development for ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

To our knowledge, this is the first-in-animal preliminary study, which used a biocompatible electrospun membrane with the addition of autologous ...

The company, along with its subsidiary NTPC Green Energy, has entered into multiple MoUs with the Madhya Pradesh government ...

For more than a decade, Michelle Hobson endured extreme fatigue, excruciating abdominal pain, and repeated hospital visits.